CMOPF

Cosmo Pharmaceuticals N.V

CMOPF, USA

Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with a faster and less risky excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Relafalk, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Byfavo, an intravenous benzodiazepine sedative/anesthetic. It is also developing Breezula, a novel androgen receptor inhibitor, which is in Phase III trials and targets androgen receptors in the scalp; Rifamycin 1% enema that is in Phase II clinical trial for the treatment of distal ulcerative colitis and proctitis; Colesevelam, which is in preclinical studies for the treatment of bile acid diarrhea; and Cortexolone 17a-valerate-21-propionate, an oral Androgen receptor and glucocorticoid receptor antagonist that is in Phase I clinical trial for treatment solid tumors, as well as provides Cosmo's AI technology, a GI Genius intelligent endoscopy system. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, RedHill Biopharma Ltd., Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

https://www.cosmopharma.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
CMOPF
stock
CMOPF

AI colonoscopy tools and new skin, hair-loss treatments mark Cosmo's shift Stock Titan

Read more →
CMOPF
stock
CMOPF

Cosmo shares skyrocket after male hair loss treatment hits key trial goals (CMOPF:OTCMKTS) Seeking Alpha

Read more →

Showing 2 of 10

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Earnings Ratio (P/E)

-

Medium

31.74

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

4.68

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-0.44 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-0.33 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-3.33 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.31

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Cosmo Pharmaceuticals N.V

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

—

Latest Release

Date

2021-03-31

EPS Actual

-0.2365

EPS Estimate

0

EPS Difference

-0.2365

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Wide Moat Company(6.3)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1.5)
Momentum
Strong Momentum(7.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(3)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-06-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.